Article

Pharmacokinetics of ceftriaxone in pediatric patients with meningitis.

Antimicrobial Agents and Chemotherapy (Impact Factor: 4.45). 03/1983; 23(2):191-4. DOI: 10.1128/AAC.23.2.191
Source: PubMed

ABSTRACT Pharmacokinetics of ceftriaxone after a single dose of 50 or 75 mg/kg were determined in 30 pediatric patients with bacterial meningitis. Data for doses of 50 and 75 mg/kg, respectively, were as follows (mean +/- standard deviation): maximum plasma concentrations, 230 +/- 64 and 295 +/- 76 mug/ml; elimination rate constant, 0.14 +/- 0.06 and 0.14 +/- 0.04 h(-1); harmonic elimination half-life, 5.8 +/- 2.8 and 5.4 +/- 2.1 h; plasma clearance, 51 +/- 24 and 55 +/- 18 ml/h per kg; volume of distribution, 382 +/- 129 and 387 +/- 56 ml/kg; mean concentration in cerebrospinal fluid 1 to 6 h after infusion, 5.4 and 6.4 mug/ml. A dosage schedule of 50 mg/kg every 12 h for bacterial meningitis caused by susceptible organisms is suggested for pediatric patients over 7 days of age.

3 Followers
 · 
304 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Ceftriaxone, a new third-generation cephalosporin, appearstobepromising forthetherapy ofacute bacterial meningitis. The90% MBCs ofceftriaxone against 54 recentcerebrospinal fluid isolates of Streptococcus pneumoniae, Neisseria meningitidis, andHaemophilus influenzae were .0.06 to0.25j.Lg/ml. We examined theefficacy andsafety ofceftriaxone therapy ofmeningitis inBahia, Brazil. Thestudy wasconducted intwophases; inphaseA,ceftriaxone was coadministered withampicillin. Themean cerebrospinal fluid concentrations ofceftriaxone 24hafter an intravenous doseof80mg/kgwere4.2and2.3,ug/ml on days4to 6and10to12oftherapy, respectively. Theseconcentrations were 8-tomore than100-fold greater thanthe 90%MBCs against therelevant pathogens. InphaseB,ceftriaxone (administered oncedaily ata doseof80 mg/kgafter an initial doseof100mg/kg) was compared withconventional dosages ofampicillin and chloramphenicol inaprospective randomized trial of36children andadults withmeningitis. Thegroupswere comparable based on clinical, laboratory, andetiological parameters. Ceftriaxone given oncedaily produced results equivalent tothose obtained withampicillin pluschloramphenicol, asjudged bycurerate, casefatality ratio, resolution withsequelae, typeandseverity ofsequelae, timetosterility ofcerebrospinal fluid, and potentially drug-related adverse effects. Thecerebrospinal fluid bactericidal titers obtained 16to24hafter ceftriaxone dosing were usually 1:512 to>1:2,048 evenlate inthetreatment course,compared withvalues of 1:8to1:32inpatients receiving ampicillin pluschloramphenicol. Ceftriaxone clearly deserves further evaluation forthetherapy ofmeningitis; theoptimal dose, dosing frequency (every 12hor every24h),and duration oftherapy remaintobedetermined.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ceftriaxone is a very well-fitted antibiotic to bacterias of pediatric infectious diseases : E. coli, H. influenzae, Streptococcus, Staphylococcus. The pharmacokinetic studies show a long half-life : 5 hours in children, 5 to 24 hours in neonates. There is no correlation in neonates between day of life, birth-weight and term; a single dose 50 mg/kg/day is sufficient in relation to efficient through levels. Six studies in 116 neonates employed a good activity and safety. But Listeria monocytogenes must be always included in the spectrum, for ceftriaxone is not effective. In 447 children infections treated were pneumonias, pleural empyemas, septicemia, U.T.I., cellulitis, osteoarthritis and severe ENT infections with only 9 failures. A single daily dose is efficient in regard to studies of Higham, Mc Closkey an Dagan. Dagan well demonstrated efficacy of intramusculary route and ambulatory treatment by a once day IM infection. The safety is good with less than 10 % adverse reactions, diarrhea and rashes. Ceftriaxone is a very useful cephalosporin in pediatrics in regard to its bacterial spectrum, administration efficacy and cost, with a shorter duration of hospitalization.
    Médecine et Maladies Infectieuses 10/1989; 19:101–106. DOI:10.1016/S0399-077X(89)80189-1 · 0.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Most clinical reports deal with series of patients or single cases under widely different circumstances as to the nature of infection, the duration and mode of chemotherapy, the means of drug concentration assessment, and the expression and interpretation of results. It is generally accepted that the penetration of β-lactamines, aminoglycosides and vancomycin into the CSF is increased in the presence of infection, and this is confirmed in the results of most animal and human studies. Fluoroquinolones, cotrimoxazole, chloramphenicol, metronidazole, penetrate well into normal meninges. Finally, the reports reviewed above provide data used in predicting the likelihood of attaining adequate CSF levels with any particular antibiotic regimen, for bacterial infection of the CNS. However, the fact that levels can be assessed in the CSF does necessarily mean that drugs are effective in the treatment of the disease. Clinical studies are necessary to provide evidence as to the efficacy of each of the agents in meningitis.
    Médecine et Maladies Infectieuses 12/1996; 26:1032-1043. DOI:10.1016/S0399-077X(96)80015-1 · 0.91 Impact Factor

Full-text (2 Sources)

Download
5 Downloads
Available from
Apr 3, 2015